Treatment of Pain and Autonomic Dysreflexia in Spinal Cord Injury With Deep Brain Stimulation
2 other identifiers
interventional
4
1 country
2
Brief Summary
The purpose of this research study is to determine if DBS is a feasible, safe and effective therapy for pain and autonomic dysreflexia after spinal cord injury.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable pain
Started Dec 2013
Longer than P75 for not_applicable pain
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 25, 2013
CompletedStudy Start
First participant enrolled
December 1, 2013
CompletedFirst Posted
Study publicly available on registry
December 10, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2017
CompletedOctober 8, 2020
October 1, 2020
3.8 years
October 25, 2013
October 2, 2020
Conditions
Outcome Measures
Primary Outcomes (3)
Change in Pain as measured by Neuropathic Pain Symptom Inventory (NPSI)
Neuropathic Pain Symptom Inventory (NPSI) is a 12 item questionnaire with each question scored form 0-10 with the highest score indicating greater pain
Baseline, up to 52 weeks
Change in Pain as measured by Multidimensional pain Inventory (MPI-SCI)
Multidimensional pain Inventory (MPI-SCI) is a self-report questionnaire consisting of 50 items, each questioned scored from 0-6, with the higher score being the greatest impact of pain on an individuals daily life.
Baseline, up to 52 weeks
Change in Pain as measured by the Basic Pain Data Set
The Basic Pain Data set is a 4 question assessing change in pain in the past week using 0-6 scale on each item with the higher score indicating greater pain intensity
Baseline, up to 52 weeks
Study Arms (1)
Deep Brain Stimulation
EXPERIMENTALDeep brain stimulation (DBS) for the alleviation of chronic neuropathic pain in patients with spinal cord injury (SCI). The stimulation will be applied bilaterally or unilaterally in the midbrain periaqueductal/periventricular gray region (PAG/PVG). Extended participation in the study, which will last approximately 2 more years, precisely 104 weeks.The purpose of this extended portion of the study is to obtain long-term follow-up information on safety and efficacy, in subjects that have opted to receive continuing brain stimulation. Investigators label weeks in terms of original enrollment. Thus the surgery occurs in weeks 7 and 8 and the original study finishes in week 52, with the extension lasting from week 53 to week 156.
Interventions
Local anesthesis, MRI and CT scan of the brain followed by implantation of the stimulation device
Eligibility Criteria
You may qualify if:
- Age 22-60 years of age
- Level of injury at or above T12
- Neuropathic pain at or below the level of injury, as determined based on pain in an area with neurological deficit and described as burning, shooting, electric, stinging etc.
- The injury must have occurred at least 1 year prior to entering the study and participants must have experienced chronic pain for a minimum of six months.
- The injury level must be at or above T12, and the disability must have a grade on the American Spinal Injury Association Impairment Scale (AIS) of ASIA-A, ASIA-B, ASIA-C or ASIA-D as determined by a qualified examiners.
- Autonomic dysreflexia can be present, but is not a requirement. This is defined as a rise of systolic pressure by more than 30 mmHg during noxious skin stimulation or when the bladder or bowel is full, or apparently spontaneously over a period of minutes.
- Pain (neuropathic) of moderate severity or greater is present, when the patient is taking medication, with a score of at least 4 on a numerical rating scale (range of 0 to 10).
- Treatment with at least two of the following drug classes must have failed to give satisfactory pain relief within the last two years: anticonvulsants e.g., pregabalin, gabapentin); antidepressants (e.g., trazodone, amitriptyline); NSAIDS (e.g., ibuprofen). In addition, at least one of the following must have proved ineffective: exercise-based rehabilitation, massage therapy using a variety of methods, acupuncture using pressure, needles, heat, or electrical stimulation on specific points on the body and psychological interventions such as cognitive therapy.
- The subject must be taking pain medication to maintain a stable level of medication from 4 weeks before surgery to 12 weeks after (the primary endpoint), except on the day of surgery.
- Participants on medications for other conditions, such as diabetes, will be considered as candidates for this study. The dose will be monitored throughout the trial. (They will be excluded if the drug is being used to treat epilepsy, Parkinson's diseases, or other brain degenerative diseases.)
- The subject must be willing to comply with the protocol including all scheduled visits.
- Literate at 8th grade level or above.
- Subject must provide a letter of clearance for the DBS surgery from primary care physician
You may not qualify if:
- Unable to give informed consent
- Prisoner or ward of the state
- Pregnancy
- Prior history of abusing nonprescribed drugs
- Recent (one-year) history of alcohol abuse
- ASIA motor exam unobtainable
- History of cardiac arrhythmia
- Renal disease, heart disease or uncontrolled hypertension (except due to autonomic dysreflexia), liver disease or hepatic cirrhosis
- Active major medical or psychiatric illness
- Significant post-traumatic encephalopathy from head trauma sustained at SCI
- Languages without local expertise
- Pain is only nociceptive, or due to muscle spasms
- Coagulopathy requiring anticoagulation therapy
- Thrombocytopenia or platelet dysfunction
- Peripheral vascular disease
- +9 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Jonathan Jagidlead
- United States Department of Defensecollaborator
Study Sites (2)
University of Miami Hospital
Miami, Florida, 33136, United States
VA Medical Center
Miami, Florida, 33136, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jonathan R Jagid, M.D.
University of Miami
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- DEVICE FEASIBILITY
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Associate Professor of Neurological Surgery and Neurology
Study Record Dates
First Submitted
October 25, 2013
First Posted
December 10, 2013
Study Start
December 1, 2013
Primary Completion
September 1, 2017
Study Completion
September 1, 2017
Last Updated
October 8, 2020
Record last verified: 2020-10
Data Sharing
- IPD Sharing
- Will not share